Faggioni M, et al. - Researchers used the multicenter PROMETHEUS observational registry to determine the use of prasugrel following percutaneous coronary intervention (PCI) in African American (AA) patients presenting with acute coronary syndrome (ACS). Overall 2,125 (11%) AA and 17,707 (89%) non-AA patients were analyzed for clinical outcomes at 90-day and 1-year. Compared to non-AA patients, AA patients were found to be younger, more often female with a higher prevalence of diabetes mellitus, chronic kidney disease, and prior coronary intervention. Findings revealed an independent association of AA race with a significantly higher risk of myocardial infarction at 90-days and 1 year post-PCI. In relation to AA race, higher risk clinical presentation and worse 1-year ischemic outcomes were observed, however, lower prasugrel prescription was independently predicted by AA race in a contemporary population of ACS patients undergoing PCI.